ILLUCCIX Drug Patent Profile
✉ Email this page to a colleague
When do Illuccix patents expire, and when can generic versions of Illuccix launch?
Illuccix is a drug marketed by Telix and is included in one NDA. There is one patent protecting this drug.
This drug has forty-two patent family members in eighteen countries.
The generic ingredient in ILLUCCIX is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
DrugPatentWatch® Generic Entry Outlook for Illuccix
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 28, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ILLUCCIX
International Patents: | 42 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 2 |
Drug Prices: | Drug price information for ILLUCCIX |
What excipients (inactive ingredients) are in ILLUCCIX? | ILLUCCIX excipients list |
DailyMed Link: | ILLUCCIX at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ILLUCCIX
Generic Entry Date for ILLUCCIX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ILLUCCIX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Grand Pharmaceutical (China) Co., Ltd. | Phase 3 |
Telix International Pty Ltd | Phase 3 |
BAMF Health | Early Phase 1 |
US Patents and Regulatory Information for ILLUCCIX
ILLUCCIX is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ILLUCCIX is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ILLUCCIX
Kit for radiolabelling
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Telix | ILLUCCIX | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 214032-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ILLUCCIX
When does loss-of-exclusivity occur for ILLUCCIX?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15309187
Estimated Expiration: ⤷ Try a Trial
Patent: 15309188
Estimated Expiration: ⤷ Try a Trial
Patent: 20220193
Estimated Expiration: ⤷ Try a Trial
Patent: 20220194
Estimated Expiration: ⤷ Try a Trial
Patent: 22202346
Estimated Expiration: ⤷ Try a Trial
Patent: 22202439
Estimated Expiration: ⤷ Try a Trial
Belgium
Patent: 21191
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2017003578
Estimated Expiration: ⤷ Try a Trial
Patent: 2017003710
Estimated Expiration: ⤷ Try a Trial
Patent: 2021017474
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 58471
Estimated Expiration: ⤷ Try a Trial
Patent: 58475
Estimated Expiration: ⤷ Try a Trial
Patent: 67294
Estimated Expiration: ⤷ Try a Trial
China
Patent: 6659806
Estimated Expiration: ⤷ Try a Trial
Patent: 6794265
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 85911
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 85911
Estimated Expiration: ⤷ Try a Trial
Patent: 85912
Estimated Expiration: ⤷ Try a Trial
Patent: 62025
Estimated Expiration: ⤷ Try a Trial
Patent: 62026
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 53971
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 0735
Estimated Expiration: ⤷ Try a Trial
Patent: 0736
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 43343
Estimated Expiration: ⤷ Try a Trial
Patent: 52622
Estimated Expiration: ⤷ Try a Trial
Patent: 17526745
Estimated Expiration: ⤷ Try a Trial
Patent: 17530188
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 17002361
Estimated Expiration: ⤷ Try a Trial
Patent: 17002362
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 9291
Estimated Expiration: ⤷ Try a Trial
Patent: 9293
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 85911
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 85911
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 24894
Estimated Expiration: ⤷ Try a Trial
Patent: 25627
Estimated Expiration: ⤷ Try a Trial
Patent: 17109582
Estimated Expiration: ⤷ Try a Trial
Patent: 17109583
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1702152
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 55991
Estimated Expiration: ⤷ Try a Trial
Patent: 56030
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ILLUCCIX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 250735 | חד-, דו- או פוליסכאריד המשמש כמעכב מתכת בהכנה של ga68-קלאט-גורם ממקד משופעל (Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent) | ⤷ Try a Trial |
Australia | 2015309188 | Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68Ga-chelate-functionalized targeting agent | ⤷ Try a Trial |
Japan | 6552622 | ⤷ Try a Trial | |
Portugal | 3185911 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |